Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.
Company profile
Ticker
MTCR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
472297384
MTCR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
24 Mar 23
8-K
Material Modifications to Rights of Security Holders
24 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 23
8-K
Departure of Directors or Certain Officers
23 Mar 23
8-K
Entry into a Material Definitive Agreement
15 Mar 23
EFFECT
Notice of effectiveness
8 Mar 23
POS AM
Prospectus update (post-effective amendment)
3 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Mar 23
25-NSE
Exchange delisting
3 Mar 23
Latest ownership filings
4
Preston Klassen
24 Mar 23
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 23
SC 13G/A
BML Investment Partners, L.P.
8 Feb 23
4
Michael York
27 Jan 23
4
Preston Klassen
27 Jan 23
4
Braden Michael Leonard
21 Dec 22
SC 13G
TANG CAPITAL PARTNERS LP
19 Dec 22
SC 13D
BML Investment Partners, L.P.
8 Dec 22
4
Braden Michael Leonard
9 Nov 22
4
Braden Michael Leonard
31 Oct 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.75 mm | 52.75 mm | 52.75 mm | 52.75 mm | 52.75 mm | 52.75 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.72 mm | 3.04 mm | 932.00 k | 3.02 mm |
Cash used (since last report) | n/a | n/a | 30.93 mm | 54.70 mm | 16.75 mm | 54.23 mm |
Cash remaining | n/a | n/a | 21.82 mm | -1.95 mm | 36.00 mm | -1.48 mm |
Runway (months of cash) | n/a | n/a | 12.7 | -0.6 | 38.6 | -0.5 |
Institutional ownership, Q1 2023
60.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 25 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.68 bn |
Total shares | 25.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BML Capital Management | 6.17 mm | $3.52 bn |
BML Investment Partners | 5.89 mm | $0.00 |
Tang Capital Partners | 4.25 mm | $0.00 |
ARCH Venture Fund VIII | 2.94 mm | $23.11 mm |
Polaris Partners VII | 2.89 mm | $22.75 mm |
JBF Capital | 1.95 mm | $1.11 bn |
Artal | 924.90 k | $528.00 k |
ARE Alexandria Real Estate Equities | 784.35 k | $529.00 k |
Wedbush Securities | 12.70 k | $7.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Mar 23 | Preston Klassen | Common Stock | Grant | Dispose A | No | No | 0.47 | 842,211 | 395.84 k | 1,384,116 |
23 Mar 23 | Preston Klassen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.47 | 842,211 | 395.84 k | 0 |
26 Jan 23 | Preston Klassen | Common Stock | Sell | Dispose S | No | No | 0.4132 | 380,605 | 157.27 k | 541,905 |
26 Jan 23 | Michael York | Common Stock | Sell | Dispose S | No | No | 0.4141 | 107,054 | 44.33 k | 103,499 |
21 Dec 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.4 | 120,099 | 48.04 k | 6,160,570 |
20 Dec 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.3791 | 50,122 | 19.00 k | 6,040,471 |
19 Dec 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.4 | 101,384 | 40.55 k | 5,990,349 |
9 Nov 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.39 | 39,816 | 15.53 k | 5,888,965 |
8 Nov 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.4 | 500 | 200.00 | 5,849,149 |
7 Nov 22 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 0.4223 | 123,954 | 52.35 k | 5,848,649 |